ITGAM and neoplasm: In tumor therapy, T cell cytotoxicity is enhanced by targeting the myeloid cell surface marker CD11b (ITGAM), resulting in the repolarization of macrophages, improvements in the responses of dendritic cells, and a decrease in myeloid-derived suppressor cells in pancreatic cancer (Bagati et al. 2021).